Австралия - английский - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - darunavir, quantity: 400 mg - tablet, film coated - excipient ingredients: sodium chloride; hyprolose; macrogol 4000; titanium dioxide; crospovidone; polacrilin potassium; iron oxide red; colloidal anhydrous silica; iron oxide yellow; purified talc; silicified microcrystalline cellulose; polyvinyl alcohol; magnesium stearate - adult patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - quetiapine 400 (as fumarate) mg - 400 (as fumarate) mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 460.5 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - moxifloxacin 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - moxifloxacin 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - norfloxacin 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - norfloxacin 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg